 | • レポートコード：MRC2-11QY02417 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はアミロイドーシス治療薬のグローバル市場について調査・分析したレポートです。種類別（AG-10、ALN-ANG、ALN-TTRsc02、CAEL-101、カナキヌマブ、その他）市場規模、用途別（ALアミロイドーシス、AAアミロイドーシス、ATTRアミロイドーシス、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別アミロイドーシス治療薬の競争状況、市場シェア ・世界のアミロイドーシス治療薬市場：種類別市場規模 2015年-2020年（AG-10、ALN-ANG、ALN-TTRsc02、CAEL-101、カナキヌマブ、その他） ・世界のアミロイドーシス治療薬市場：種類別市場規模予測 2021年-2026年（AG-10、ALN-ANG、ALN-TTRsc02、CAEL-101、カナキヌマブ、その他） ・世界のアミロイドーシス治療薬市場：用途別市場規模 2015年-2020年（ALアミロイドーシス、AAアミロイドーシス、ATTRアミロイドーシス、その他） ・世界のアミロイドーシス治療薬市場：用途別市場規模予測 2021年-2026年（ALアミロイドーシス、AAアミロイドーシス、ATTRアミロイドーシス、その他） ・北米のアミロイドーシス治療薬市場分析：米国、カナダ ・ヨーロッパのアミロイドーシス治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのアミロイドーシス治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のアミロイドーシス治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのアミロイドーシス治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer Inc.、ProteoTech, Inc.、Alnylam Pharmaceuticals, Inc.、Arcturus Therapeutics, Inc、Bellus Health Inc.、Bsim2、Celgene Corporation、Millennium Pharmaceuticals, Inc.、Onyx Pharmaceuticals, Inc.、GlaxoSmithKline Plc、Isis Pharmaceuticals, Inc.、Prothena Corporation Plc、SOM Innovation Biotech SL ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Amyloidosis Therapeutics Market
The global Amyloidosis Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Amyloidosis Therapeutics Scope and Market Size
Amyloidosis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Amyloidosis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Amyloidosis Therapeutics market is segmented into
AG-10
ALN-ANG
ALN-TTRsc02
CAEL-101
canakinumab
Others
Segment by Application, the Amyloidosis Therapeutics market is segmented into
AL amyloidosis
AA amyloidoses
ATTR amyloidoses
Others
Regional and Country-level Analysis
The Amyloidosis Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Amyloidosis Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Amyloidosis Therapeutics Market Share Analysis
Amyloidosis Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Amyloidosis Therapeutics business, the date to enter into the Amyloidosis Therapeutics market, Amyloidosis Therapeutics product introduction, recent developments, etc.
The major vendors covered:
Pfizer Inc.
ProteoTech, Inc.
Alnylam Pharmaceuticals, Inc.
Arcturus Therapeutics, Inc
Bellus Health Inc.
Bsim2
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Isis Pharmaceuticals, Inc.
Prothena Corporation Plc
SOM Innovation Biotech SL
1 Study Coverage
1.1 Amyloidosis Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Amyloidosis Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Amyloidosis Therapeutics Market Size Growth Rate by Type
1.4.2 AG-10
1.4.3 ALN-ANG
1.4.4 ALN-TTRsc02
1.4.5 CAEL-101
1.4.6 canakinumab
1.4.7 Others
1.5 Market by Application
1.5.1 Global Amyloidosis Therapeutics Market Size Growth Rate by Application
1.5.2 AL amyloidosis
1.5.3 AA amyloidoses
1.5.4 ATTR amyloidoses
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Amyloidosis Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Amyloidosis Therapeutics Revenue 2015-2026
2.1.2 Global Amyloidosis Therapeutics Sales 2015-2026
2.2 Global Amyloidosis Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Amyloidosis Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Amyloidosis Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Amyloidosis Therapeutics Competitor Landscape by Players
3.1 Amyloidosis Therapeutics Sales by Manufacturers
3.1.1 Amyloidosis Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Amyloidosis Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Amyloidosis Therapeutics Revenue by Manufacturers
3.2.1 Amyloidosis Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Amyloidosis Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Amyloidosis Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Amyloidosis Therapeutics Revenue in 2019
3.2.5 Global Amyloidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Amyloidosis Therapeutics Price by Manufacturers
3.4 Amyloidosis Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Amyloidosis Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Amyloidosis Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Amyloidosis Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Amyloidosis Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Amyloidosis Therapeutics Sales by Type (2015-2020)
4.1.2 Global Amyloidosis Therapeutics Revenue by Type (2015-2020)
4.1.3 Amyloidosis Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Amyloidosis Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Amyloidosis Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Amyloidosis Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Amyloidosis Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Amyloidosis Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Amyloidosis Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Amyloidosis Therapeutics Sales by Application (2015-2020)
5.1.2 Global Amyloidosis Therapeutics Revenue by Application (2015-2020)
5.1.3 Amyloidosis Therapeutics Price by Application (2015-2020)
5.2 Amyloidosis Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Amyloidosis Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Amyloidosis Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Amyloidosis Therapeutics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Amyloidosis Therapeutics by Country
6.1.1 North America Amyloidosis Therapeutics Sales by Country
6.1.2 North America Amyloidosis Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Amyloidosis Therapeutics Market Facts & Figures by Type
6.3 North America Amyloidosis Therapeutics Market Facts & Figures by Application
7 Europe
7.1 Europe Amyloidosis Therapeutics by Country
7.1.1 Europe Amyloidosis Therapeutics Sales by Country
7.1.2 Europe Amyloidosis Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Amyloidosis Therapeutics Market Facts & Figures by Type
7.3 Europe Amyloidosis Therapeutics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Amyloidosis Therapeutics by Region
8.1.1 Asia Pacific Amyloidosis Therapeutics Sales by Region
8.1.2 Asia Pacific Amyloidosis Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Amyloidosis Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Amyloidosis Therapeutics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Amyloidosis Therapeutics by Country
9.1.1 Latin America Amyloidosis Therapeutics Sales by Country
9.1.2 Latin America Amyloidosis Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Amyloidosis Therapeutics Market Facts & Figures by Type
9.3 Central & South America Amyloidosis Therapeutics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Amyloidosis Therapeutics by Country
10.1.1 Middle East and Africa Amyloidosis Therapeutics Sales by Country
10.1.2 Middle East and Africa Amyloidosis Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Amyloidosis Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Amyloidosis Therapeutics Market Facts & Figures by Application
11 Company Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Corporation Information
11.1.2 Pfizer Inc. Description and Business Overview
11.1.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Inc. Amyloidosis Therapeutics Products Offered
11.1.5 Pfizer Inc. Related Developments
11.2 ProteoTech, Inc.
11.2.1 ProteoTech, Inc. Corporation Information
11.2.2 ProteoTech, Inc. Description and Business Overview
11.2.3 ProteoTech, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 ProteoTech, Inc. Amyloidosis Therapeutics Products Offered
11.2.5 ProteoTech, Inc. Related Developments
11.3 Alnylam Pharmaceuticals, Inc.
11.3.1 Alnylam Pharmaceuticals, Inc. Corporation Information
11.3.2 Alnylam Pharmaceuticals, Inc. Description and Business Overview
11.3.3 Alnylam Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Products Offered
11.3.5 Alnylam Pharmaceuticals, Inc. Related Developments
11.4 Arcturus Therapeutics, Inc
11.4.1 Arcturus Therapeutics, Inc Corporation Information
11.4.2 Arcturus Therapeutics, Inc Description and Business Overview
11.4.3 Arcturus Therapeutics, Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Products Offered
11.4.5 Arcturus Therapeutics, Inc Related Developments
11.5 Bellus Health Inc.
11.5.1 Bellus Health Inc. Corporation Information
11.5.2 Bellus Health Inc. Description and Business Overview
11.5.3 Bellus Health Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bellus Health Inc. Amyloidosis Therapeutics Products Offered
11.5.5 Bellus Health Inc. Related Developments
11.6 Bsim2
11.6.1 Bsim2 Corporation Information
11.6.2 Bsim2 Description and Business Overview
11.6.3 Bsim2 Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bsim2 Amyloidosis Therapeutics Products Offered
11.6.5 Bsim2 Related Developments
11.7 Celgene Corporation
11.7.1 Celgene Corporation Corporation Information
11.7.2 Celgene Corporation Description and Business Overview
11.7.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Celgene Corporation Amyloidosis Therapeutics Products Offered
11.7.5 Celgene Corporation Related Developments
11.8 Millennium Pharmaceuticals, Inc.
11.8.1 Millennium Pharmaceuticals, Inc. Corporation Information
11.8.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
11.8.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Products Offered
11.8.5 Millennium Pharmaceuticals, Inc. Related Developments
11.9 Onyx Pharmaceuticals, Inc.
11.9.1 Onyx Pharmaceuticals, Inc. Corporation Information
11.9.2 Onyx Pharmaceuticals, Inc. Description and Business Overview
11.9.3 Onyx Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Products Offered
11.9.5 Onyx Pharmaceuticals, Inc. Related Developments
11.10 GlaxoSmithKline Plc
11.10.1 GlaxoSmithKline Plc Corporation Information
11.10.2 GlaxoSmithKline Plc Description and Business Overview
11.10.3 GlaxoSmithKline Plc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Products Offered
11.10.5 GlaxoSmithKline Plc Related Developments
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Corporation Information
11.1.2 Pfizer Inc. Description and Business Overview
11.1.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Inc. Amyloidosis Therapeutics Products Offered
11.1.5 Pfizer Inc. Related Developments
11.12 Prothena Corporation Plc
11.12.1 Prothena Corporation Plc Corporation Information
11.12.2 Prothena Corporation Plc Description and Business Overview
11.12.3 Prothena Corporation Plc Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Prothena Corporation Plc Products Offered
11.12.5 Prothena Corporation Plc Related Developments
11.13 SOM Innovation Biotech SL
11.13.1 SOM Innovation Biotech SL Corporation Information
11.13.2 SOM Innovation Biotech SL Description and Business Overview
11.13.3 SOM Innovation Biotech SL Sales, Revenue and Gross Margin (2015-2020)
11.13.4 SOM Innovation Biotech SL Products Offered
11.13.5 SOM Innovation Biotech SL Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Amyloidosis Therapeutics Market Estimates and Projections by Region
12.1.1 Global Amyloidosis Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Amyloidosis Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Amyloidosis Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Amyloidosis Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Amyloidosis Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Amyloidosis Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Amyloidosis Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Amyloidosis Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Amyloidosis Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Amyloidosis Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Amyloidosis Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Amyloidosis Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Amyloidosis Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Amyloidosis Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Amyloidosis Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Amyloidosis Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Amyloidosis Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Amyloidosis Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Amyloidosis Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Amyloidosis Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Amyloidosis Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Amyloidosis Therapeutics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Amyloidosis Therapeutics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Amyloidosis Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Amyloidosis Therapeutics Market Segments
Table 2. Ranking of Global Top Amyloidosis Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Amyloidosis Therapeutics Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of AG-10
Table 5. Major Manufacturers of ALN-ANG
Table 6. Major Manufacturers of ALN-TTRsc02
Table 7. Major Manufacturers of CAEL-101
Table 8. Major Manufacturers of canakinumab
Table 9. Major Manufacturers of Others
Table 10. Global Amyloidosis Therapeutics Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Amyloidosis Therapeutics Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Amyloidosis Therapeutics Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Amyloidosis Therapeutics Sales Market Share by Regions (2015-2020)
Table 14. Global Amyloidosis Therapeutics Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Amyloidosis Therapeutics Sales by Manufacturers (2015-2020) (K Pcs)
Table 16. Global Amyloidosis Therapeutics Sales Share by Manufacturers (2015-2020)
Table 17. Global Amyloidosis Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 18. Global Amyloidosis Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Amyloidosis Therapeutics as of 2019)
Table 19. Amyloidosis Therapeutics Revenue by Manufacturers (2015-2020) (US$ Million)
Table 20. Amyloidosis Therapeutics Revenue Share by Manufacturers (2015-2020)
Table 21. Key Manufacturers Amyloidosis Therapeutics Price (2015-2020) (USD/Pcs)
Table 22. Amyloidosis Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Amyloidosis Therapeutics Product Type
Table 24. Date of International Manufacturers Enter into Amyloidosis Therapeutics Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 27. Global Amyloidosis Therapeutics Sales Share by Type (2015-2020)
Table 28. Global Amyloidosis Therapeutics Revenue by Type (2015-2020) (US$ Million)
Table 29. Global Amyloidosis Therapeutics Revenue Share by Type (2015-2020)
Table 30. Amyloidosis Therapeutics Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 31. Global Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 32. Global Amyloidosis Therapeutics Sales Share by Application (2015-2020)
Table 33. North America Amyloidosis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 34. North America Amyloidosis Therapeutics Sales Market Share by Country (2015-2020)
Table 35. North America Amyloidosis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 36. North America Amyloidosis Therapeutics Revenue Market Share by Country (2015-2020)
Table 37. North America Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 38. North America Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Table 39. North America Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 40. North America Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Table 41. Europe Amyloidosis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 42. Europe Amyloidosis Therapeutics Sales Market Share by Country (2015-2020)
Table 43. Europe Amyloidosis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 44. Europe Amyloidosis Therapeutics Revenue Market Share by Country (2015-2020)
Table 45. Europe Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 46. Europe Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Table 47. Europe Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 48. Europe Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Table 49. Asia Pacific Amyloidosis Therapeutics Sales by Region (2015-2020) (K Pcs)
Table 50. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Region (2015-2020)
Table 51. Asia Pacific Amyloidosis Therapeutics Revenue by Region (2015-2020) (US$ Million)
Table 52. Asia Pacific Amyloidosis Therapeutics Revenue Market Share by Region (2015-2020)
Table 53. Asia Pacific Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 54. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Table 55. Asia Pacific Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 56. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Table 57. Latin America Amyloidosis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 58. Latin America Amyloidosis Therapeutics Sales Market Share by Country (2015-2020)
Table 59. Latin Americaa Amyloidosis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 60. Latin America Amyloidosis Therapeutics Revenue Market Share by Country (2015-2020)
Table 61. Latin America Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 62. Latin America Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Table 63. Latin America Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 64. Latin America Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Table 65. Middle East and Africa Amyloidosis Therapeutics Sales by Country (2015-2020) (K Pcs)
Table 66. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Country (2015-2020)
Table 67. Middle East and Africa Amyloidosis Therapeutics Revenue by Country (2015-2020) (US$ Million)
Table 68. Middle East and Africa Amyloidosis Therapeutics Revenue Market Share by Country (2015-2020)
Table 69. Middle East and Africa Amyloidosis Therapeutics Sales by Type (2015-2020) (K Pcs)
Table 70. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Table 71. Middle East and Africa Amyloidosis Therapeutics Sales by Application (2015-2020) (K Pcs)
Table 72. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Table 73. Pfizer Inc. Corporation Information
Table 74. Pfizer Inc. Description and Major Businesses
Table 75. Pfizer Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Pfizer Inc. Product
Table 77. Pfizer Inc. Recent Development
Table 78. ProteoTech, Inc. Corporation Information
Table 79. ProteoTech, Inc. Description and Major Businesses
Table 80. ProteoTech, Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. ProteoTech, Inc. Product
Table 82. ProteoTech, Inc. Recent Development
Table 83. Alnylam Pharmaceuticals, Inc. Corporation Information
Table 84. Alnylam Pharmaceuticals, Inc. Description and Major Businesses
Table 85. Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Alnylam Pharmaceuticals, Inc. Product
Table 87. Alnylam Pharmaceuticals, Inc. Recent Development
Table 88. Arcturus Therapeutics, Inc Corporation Information
Table 89. Arcturus Therapeutics, Inc Description and Major Businesses
Table 90. Arcturus Therapeutics, Inc Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Arcturus Therapeutics, Inc Product
Table 92. Arcturus Therapeutics, Inc Recent Development
Table 93. Bellus Health Inc. Corporation Information
Table 94. Bellus Health Inc. Description and Major Businesses
Table 95. Bellus Health Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Bellus Health Inc. Product
Table 97. Bellus Health Inc. Recent Development
Table 98. Bsim2 Corporation Information
Table 99. Bsim2 Description and Major Businesses
Table 100. Bsim2 Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Bsim2 Product
Table 102. Bsim2 Recent Development
Table 103. Celgene Corporation Corporation Information
Table 104. Celgene Corporation Description and Major Businesses
Table 105. Celgene Corporation Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Celgene Corporation Product
Table 107. Celgene Corporation Recent Development
Table 108. Millennium Pharmaceuticals, Inc. Corporation Information
Table 109. Millennium Pharmaceuticals, Inc. Description and Major Businesses
Table 110. Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Millennium Pharmaceuticals, Inc. Product
Table 112. Millennium Pharmaceuticals, Inc. Recent Development
Table 113. Onyx Pharmaceuticals, Inc. Corporation Information
Table 114. Onyx Pharmaceuticals, Inc. Description and Major Businesses
Table 115. Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Onyx Pharmaceuticals, Inc. Product
Table 117. Onyx Pharmaceuticals, Inc. Recent Development
Table 118. GlaxoSmithKline Plc Corporation Information
Table 119. GlaxoSmithKline Plc Description and Major Businesses
Table 120. GlaxoSmithKline Plc Amyloidosis Therapeutics Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. GlaxoSmithKline Plc Product
Table 122. GlaxoSmithKline Plc Recent Development
Table 123. Isis Pharmaceuticals, Inc. Corporation Information
Table 124. Isis Pharmaceuticals, Inc. Description and Major Businesses
Table 125. Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Isis Pharmaceuticals, Inc. Product
Table 127. Isis Pharmaceuticals, Inc. Recent Development
Table 128. Prothena Corporation Plc Corporation Information
Table 129. Prothena Corporation Plc Description and Major Businesses
Table 130. Prothena Corporation Plc Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. Prothena Corporation Plc Product
Table 132. Prothena Corporation Plc Recent Development
Table 133. SOM Innovation Biotech SL Corporation Information
Table 134. SOM Innovation Biotech SL Description and Major Businesses
Table 135. SOM Innovation Biotech SL Amyloidosis Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 136. SOM Innovation Biotech SL Product
Table 137. SOM Innovation Biotech SL Recent Development
Table 138. Global Amyloidosis Therapeutics Sales Forecast by Regions (2021-2026) (K Pcs)
Table 139. Global Amyloidosis Therapeutics Sales Market Share Forecast by Regions (2021-2026)
Table 140. Global Amyloidosis Therapeutics Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 141. Global Amyloidosis Therapeutics Revenue Market Share Forecast by Regions (2021-2026)
Table 142. North America: Amyloidosis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 143. North America: Amyloidosis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Europe: Amyloidosis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 145. Europe: Amyloidosis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 146. Asia Pacific: Amyloidosis Therapeutics Sales Forecast by Region (2021-2026) (K Pcs)
Table 147. Asia Pacific: Amyloidosis Therapeutics Revenue Forecast by Region (2021-2026) (US$ Million)
Table 148. Latin America: Amyloidosis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 149. Latin America: Amyloidosis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 150. Middle East and Africa: Amyloidosis Therapeutics Sales Forecast by Country (2021-2026) (K Pcs)
Table 151. Middle East and Africa: Amyloidosis Therapeutics Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 153. Key Challenges
Table 154. Market Risks
Table 155. Main Points Interviewed from Key Amyloidosis Therapeutics Players
Table 156. Amyloidosis Therapeutics Customers List
Table 157. Amyloidosis Therapeutics Distributors List
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Amyloidosis Therapeutics Product Picture
Figure 2. Global Amyloidosis Therapeutics Sales Market Share by Type in 2020 & 2026
Figure 3. AG-10 Product Picture
Figure 4. ALN-ANG Product Picture
Figure 5. ALN-TTRsc02 Product Picture
Figure 6. CAEL-101 Product Picture
Figure 7. canakinumab Product Picture
Figure 8. Others Product Picture
Figure 9. Global Amyloidosis Therapeutics Sales Market Share by Application in 2020 & 2026
Figure 10. AL amyloidosis
Figure 11. AA amyloidoses
Figure 12. ATTR amyloidoses
Figure 13. Others
Figure 14. Amyloidosis Therapeutics Report Years Considered
Figure 15. Global Amyloidosis Therapeutics Market Size 2015-2026 (US$ Million)
Figure 16. Global Amyloidosis Therapeutics Sales 2015-2026 (K Pcs)
Figure 17. Global Amyloidosis Therapeutics Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Amyloidosis Therapeutics Sales Market Share by Region (2015-2020)
Figure 19. Global Amyloidosis Therapeutics Sales Market Share by Region in 2019
Figure 20. Global Amyloidosis Therapeutics Revenue Market Share by Region (2015-2020)
Figure 21. Global Amyloidosis Therapeutics Revenue Market Share by Region in 2019
Figure 22. Global Amyloidosis Therapeutics Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Amyloidosis Therapeutics Revenue in 2019
Figure 24. Amyloidosis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Amyloidosis Therapeutics Sales Market Share by Type (2015-2020)
Figure 26. Global Amyloidosis Therapeutics Sales Market Share by Type in 2019
Figure 27. Global Amyloidosis Therapeutics Revenue Market Share by Type (2015-2020)
Figure 28. Global Amyloidosis Therapeutics Revenue Market Share by Type in 2019
Figure 29. Global Amyloidosis Therapeutics Market Share by Price Range (2015-2020)
Figure 30. Global Amyloidosis Therapeutics Sales Market Share by Application (2015-2020)
Figure 31. Global Amyloidosis Therapeutics Sales Market Share by Application in 2019
Figure 32. Global Amyloidosis Therapeutics Revenue Market Share by Application (2015-2020)
Figure 33. Global Amyloidosis Therapeutics Revenue Market Share by Application in 2019
Figure 34. North America Amyloidosis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 35. North America Amyloidosis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Amyloidosis Therapeutics Sales Market Share by Country in 2019
Figure 37. North America Amyloidosis Therapeutics Revenue Market Share by Country in 2019
Figure 38. U.S. Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. U.S. Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. Canada Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Amyloidosis Therapeutics Market Share by Type in 2019
Figure 43. North America Amyloidosis Therapeutics Market Share by Application in 2019
Figure 44. Europe Amyloidosis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 45. Europe Amyloidosis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Amyloidosis Therapeutics Sales Market Share by Country in 2019
Figure 47. Europe Amyloidosis Therapeutics Revenue Market Share by Country in 2019
Figure 48. Germany Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Germany Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. France Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. U.K. Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Italy Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Russia Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Amyloidosis Therapeutics Market Share by Type in 2019
Figure 59. Europe Amyloidosis Therapeutics Market Share by Application in 2019
Figure 60. Asia Pacific Amyloidosis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 61. Asia Pacific Amyloidosis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Amyloidosis Therapeutics Sales Market Share by Region in 2019
Figure 63. Asia Pacific Amyloidosis Therapeutics Revenue Market Share by Region in 2019
Figure 64. China Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. China Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. South Korea Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. India Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Australia Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Taiwan Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Indonesia Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Thailand Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Malaysia Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Philippines Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Vietnam Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Amyloidosis Therapeutics Market Share by Type in 2019
Figure 87. Asia Pacific Amyloidosis Therapeutics Market Share by Application in 2019
Figure 88. Latin America Amyloidosis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 89. Latin America Amyloidosis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Amyloidosis Therapeutics Sales Market Share by Country in 2019
Figure 91. Latin America Amyloidosis Therapeutics Revenue Market Share by Country in 2019
Figure 92. Mexico Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Mexico Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Brazil Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Argentina Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Amyloidosis Therapeutics Market Share by Type in 2019
Figure 99. Latin America Amyloidosis Therapeutics Market Share by Application in 2019
Figure 100. Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate 2015-2020 (K Pcs)
Figure 101. Middle East and Africa Amyloidosis Therapeutics Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Amyloidosis Therapeutics Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Amyloidosis Therapeutics Revenue Market Share by Country in 2019
Figure 104. Turkey Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Turkey Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. Saudi Arabia Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Amyloidosis Therapeutics Sales Growth Rate (2015-2020) (K Pcs)
Figure 109. U.A.E Amyloidosis Therapeutics Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Amyloidosis Therapeutics Market Share by Type in 2019
Figure 111. Middle East and Africa Amyloidosis Therapeutics Market Share by Application in 2019
Figure 112. North America Amyloidosis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. North America Amyloidosis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Europe Amyloidosis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Europe Amyloidosis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Asia Pacific Amyloidosis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Asia Pacific Amyloidosis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Latin America Amyloidosis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Latin America Amyloidosis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. Middle East and Africa Amyloidosis Therapeutics Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Porter's Five Forces Analysis
Figure 123. Channels of Distribution
Figure 124. Distributors Profiles
Figure 125. Bottom-up and Top-down Approaches for This Report
Figure 126. Data Triangulation
Figure 127. Key Executives Interviewed
トランスサイレチンアミロイドーシス（ATTR）の世界市場（～2026年） Transthyretin Amyloidosis (ATTR) is an autosomal dominant hereditary disease that occurs due to deposition of variant TTR (transthyretin) protein in humans. It is mainly characterized into two main types i.e. Hereditary ATTR (hATTR) and Wild-Type (wt) ATTR. While Hereditary ATTR is caused by point m…- 血友病A・B治療材料の世界市場（～2026年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. Novel treatments for people suffering from hemophilia and other different bleeding problems h…
- 犬インフルエンザ治療薬の世界市場（～2026年） Canine flu, which is also called dog flu; is a contagious disease that affects the dog’s respiratory system. It is mainly caused by canine influenza virus/Type An influenza virus. There are two types of influenza viruses H3N2 virus H3N8 virus. Market Analysis and Insights: Global Canine Flu Therapeu…
- 全身性乾癬治療薬の世界市場（～2026年） Psoriasis is an autoimmune skin disease that causes scaling, skin redness and irritation. Psoriasis causes red, scaly patches that are generally found on the elbows, fingernails, scalp, palms, knees, face, feet and inside the mouth. Factors that can trigger psoriasis include infections, heavy alcoho…
- 痛風治療薬の世界市場（～2026年） Gout is a physical conditions that affects the patient’s ability to move, often also termed as unwalkable disease, and it has been around for centuries. Increased research and development in the field has yielded significantly more effective medications in the recent times, which are recommended to …